Skip to content
2000
Volume 19, Issue 12
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Tumor-targeting peptides have been generally developed for the overexpression of tumor specific receptors in cancer cells. The use of specific radiolabeled peptide allows tumor visualization by single photon emission computed tomography (SPECT) and positron emission tomography (PET) tools. The high affinity and specific binding of radiolabeled peptide are focusing on tumoral receptors. The character of the peptide itself, in particular, its complex molecular structure and behaviors influence on its specific interaction with receptors which are overexpressed in tumor. This review summarizes various strategies which are applied for the expansion of radiolabeled peptides for tumor targeting based on in vitro and in vivo specific tumor data and then their data were compared to find any correlation between these experiments. With a careful look at previous studies, it can be found that in vitro unblock-block ratio was unable to correlate the tumor to muscle ratio and the success of radiolabeled peptide for in vivo tumor targeting. The introduction of modifiers’ approaches, nature of peptides, and type of chelators and co-ligands have mixed effect on the in vitro and in vivo specificity of radiolabeled peptides.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/1389557519666190304120011
2019-07-01
2025-07-07
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/1389557519666190304120011
Loading

  • Article Type:
    Review Article
Keyword(s): 99mTc; peptide; radiolabeled; Radiopharmaceutical; SPECT; tumor
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test